Clarity Pharmaceuticals (CU6) - Therapeutically Driven
We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $2.78/sh (unrisked $7.41/sh).
368 Views
Clarity Pharmaceuticals (CU6) - Copper Takes a Bigger Chunk of the Pie
We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $2.13/sh (unrisked $5.15/sh).
518 Views
Clarity Pharmaceuticals (CU6) - Copper Firing: PSMA Tx and Dx Updates
Clarity have announced additional data from their Phase I/IIa SECuRE trial in metastatic castrate resistant prostate cancer (mCRPC).
298 Views
Clarity Pharmaceuticals (CU6) - No Prostates Left Behind
We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $1.55/sh (unrisked $5.19/sh).
478 Views
Clarity Pharmaceuticals (CU6)M - SECuRE Cohort 2 Data Impresses
Two of the three patients experienced ~90% PSA reductions, which is an impressive response considering this is following just one 8GBq dose.
362 Views